Keosys - Medical Imaging Software

What Keosys - Medical Imaging Software does

Based in Saint-Herblain, France and operating in the medical imaging software domain since 2001, the company has evolved into a global clinical trial services provider specializing in medical imaging and clinical endpoint management for pharmaceutical and biotechnology sponsors. Its core offering spans five service lines — Cardiac Safety (cardiovascular monitoring), Central Imaging (clinical imaging across therapeutic areas and development phases), Respiratory (patient-centric respiratory endpoints and lung imaging), e-Clinical (site and patient device solutions), and Endpoint Adjudication (scientific board-led review and regulatory compliance) — supported by project & data management, regulatory, site support, provisioning, and R&D functions.

The technical foundation is a proprietary end-to-end platform developed in-house, described as incorporating AI tools and biosensors and tailored per study. Service delivery follows a per-study engagement model with custom workflows, dedicated scientific board oversight, and 24/7 support across tri-regional offices in Europe, North America, and Asia-Pacific. The 2025 integration of Fluidda added functional respiratory imaging to the platform, extending the respiratory vertical.

The business model is B2B enterprise professional services: pricing is quote-based (no public rates), with consultative sales engagement targeting pharmaceutical and biotechnology companies conducting clinical trials across indications including oncology, respiratory, and cardiovascular disease. The company remains private, originated as a family business, and has grown organically over 25 years without disclosed institutional capital. Leadership currently consists of two CEOs (Arthur Painvin and Frédéric Kleindienst) alongside founder Pierre Tervé as Chief Scientific Officer & Co-Founder.

Name

Keosys - Medical Imaging Software

Legal name

Banook

Website

https://keosys.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Keosys is a France-based medical imaging software and clinical trial services provider serving pharmaceutical and biotechnology sponsors with proprietary, AI-enabled imaging and endpoint adjudication across cardiology, oncology, and respiratory indications globally.

Ownership category

akta.pro rank

Product category

Medical Imaging Software

NAICS

Testing Laboratories and Services (54138), Diagnostic Imaging Centers (621512)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL)

akta.pro secondary industry

Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI)

Keywords

• Medical imaging software
• Radiology imaging solutions
• Nuclear medicine imaging
• DICOM imaging software
• Diagnostic imaging readers

Headquarters

HQ city

Saint-herblain

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Clinical Trial Services: B2B service revenue generated through provision of specialized clinical trial services including cardiac safety monitoring, central imaging, respiratory services, e-clinical solutions, and endpoint adjudication for pharmaceutical companies conducting clinical trials

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Keosys develops medical imaging reading software specialized for Radiology modalities (Computed Radiography, Computed Tomography, Mammography, and Magnetic Resonance Imaging) and Nuclear Medicine modalities (PET/CT, SPECT/CT, PET/MRI). The software supports diagnostic image viewing, reading, and analysis workflows for healthcare providers handling radiological and nuclear medicine examinations across multiple imaging modalities within a single product platform.

Product overview

Banook is a clinical trials response and medical imaging services provider offering a unified portfolio of services through its proprietary in-house developed end-to-end platform. The portfolio consists of five core service lines: Cardiac Safety (cardiovascular monitoring), Central Imaging (clinical imaging across therapeutic areas), Respiratory (respiratory endpoints and lung imaging), e-Clinical (site and patient solutions with devices), and Endpoint Adjudication (scientific board review and regulatory compliance). Additional supporting services include Project & Data Management, Regulatory, Site Support, Provisioning, and Research & Development. The company has recently announced integration with Fluidda, expanding its respiratory imaging capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Keosys Imaging Reading Software Medical imaging reading and viewing software supporting both Radiology modalities (Computed Radiography, Computed Tomography, Mammography, and Magnetic Resonance Imaging) and Nuclear Medicine modalities (PET/CT, SPECT/CT, PET/MRI) for healthcare providers and diagnostic imaging departments.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Clario: Clario (formed from the merger of BioClinica and ERT) is the dominant specialty imaging and cardiac safety CRO for clinical trials. It directly competes with Banook in central imaging, cardiac safety, and e-Clinical solutions across pharma and biotech sponsors.
• Medpace: Mid-sized full-service CRO with strong therapeutic expertise and embedded imaging/biomarker capabilities. Comparable to Banook in mid-sized pharma/biotech sponsor focus and scientific board-driven service model.
• Worldwide Clinical Trials: Mid-sized specialty CRO focused on complex clinical trials across multiple therapeutic areas including neuroscience, cardiovascular, and rare diseases. Comparable to Banook in sponsor mix and consultative service model.
• Celerion: Early-phase clinical research organization with expertise in cardiac safety, respiratory, and bioequivalence studies. Comparable to Banook in therapeutic specialization and scientific board-driven approach.
• IXICO: Specialized imaging CRO providing quantitative imaging biomarkers for neurological and oncology clinical trials. Closely comparable to Banook's central imaging service line in pharma/biotech sponsor focus.

Broad incumbents

• ICON plc: One of the world's largest CROs following its PRA Health Sciences acquisition, with broad central imaging and clinical endpoint adjudication services. Competes with Banook on enterprise pharma contracts and global trial execution.
• IQVIA: The largest global CRO and clinical technology provider, offering central imaging, cardiac safety, and endpoint adjudication as part of a much broader portfolio. Banook competes against IQVIA primarily on specialty depth and independent service quality.
• Parexel International: Large global CRO (now private-equity-owned) with significant central imaging and clinical endpoint services. Overlaps with Banook in pharma clinical trial services and respiratory/cardiac safety offerings.

Emerging players

• Resonance Health: Specialist medical imaging analysis company providing quantitative imaging biomarkers for clinical trials and diagnostics. Comparable to Banook's central imaging and respiratory imaging services for pharmaceutical sponsors.
• Optellum: AI-driven lung imaging decision support platform targeting lung cancer and respiratory disease. Comparable to Banook's respiratory imaging focus (especially post-Fluidda integration) and AI-enabled clinical imaging strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/keosys
• Facebookfacebook.com/Keosys-177659282286207
• LinkedInlinkedin.com/company/keosys-sas

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Keosys - Medical Imaging Software